O4‐07‐03: Pathologic Validation of the Eadc‐adni Harmonized Hippocampal Protocol

Apostolova, Liana G.; Zarow, Chris; Biado, Kristina; Hurtz, Sona; Boccardi, Marina; Somme, Johanne; Honarpisheh, Hedieh; Blanken, Anna E.; Brook, Jenny; Ng, Denise; Alger, J. R.; Vinters, Harry V.; Bocchetta, Martina; Duvernoy, Henri M.; Jack, Clifford R.; Frisoni, Giovanni

doi:10.1016/j.jalz.2014.04.423

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We interpret our lack of evidence for tau-positive immunoreactivity in Stratum lacunosum-moleculare as a different pattern of distribution of Tau material in FTLD-TDP. In this regard, selective Tau pathology in CA2 has also been reported in another form of neurodegenerative disease, Argyrophilic Grain Disease, (Apostolova et al, 2015;Yokota et al, 2007), as well as in Primary Age-Related Tauopathy (PART) (Walker et al, 2021). This data calls for further research to determine detailed topographical differences in the pattern of tau-positive cells in the hippocampus.…”

Section: Alzheimer Diseasementioning

confidence: 87%

The CA2 hippocampal subfield in humans: A review

2023

View full text Add to dashboard Cite

CA2 is probably the most enigmatic of the hippocampal fields. It is small in size (in humans about 500 μm across the mediolateral axis), and yet, it is involved in important functions, such as in social memory and anxiety. This study offers a glimpse of several significant aspects of the anatomical organization of CA2. We present an overview of the anatomical structure of CA2, imbued in the general organization of the human hippocampal formation. The location and distinctiveness of CA2 is presented in relation with CA3 and CA1, based in a total of 23 human control cases serially sectioned throughout the whole longitudinal axis of the hippocampus, examined every 500 μm in Nissl-stained sections. The longitudinal extent of CA2 is close to 30 mm, starting in the hippocampal head, 2.5 mm caudal to the DG and 3.5 mm caudal to the start of CA3, approximately 10 mm from the hippocampus rostral end.The connectional information of human CA2 is very scarce, thereby we relied on nonhuman primate tract tracing studies of the hippocampal formation, given its resemblance to the human brain. Human CA2 is subject of neuropathological studies, and we chose to present Alzheimer's disease, schizophrenia, and Mesial Temporal Lobe Epilepsy with hippocampal sclerosis in those aspects that impinge directly into CA2.

show abstract

Section: Alzheimer Diseasementioning

confidence: 87%

The CA2 hippocampal subfield in humans: A review

2023

View full text Add to dashboard Cite

show abstract

“…Reportedly it may be detectable in the amnestic mild cognitive impairment (aMCI) stage, and even before symptoms are noticed, perhaps 10 years before dementia is usually diagnosed [17,18]. In later stages it correlates roughly with the severity of cognitive loss [19] and strongly with Braak and Braak stages of AD [20] As a biomarker for AD it has been commended variously, as "the best-established", [21] "the most established... to date", [22] and "one of the best…" [13].…”

Section: Discussionmentioning

confidence: 99%

Diagnosis of amyloid-positive mild cognitive impairment using structural magnetic resonance imaging: The worth of multiple regions of interest

2015

Integr Mol Med

View full text Add to dashboard Cite

Objective: Briefly to compare twin and multiple regions of interest (ROIs) in structural magnetic resonance images (sMRI), testing two statistical parametric mapping (SPM) packages against amyloid status in patients diagnosed with mild cognitive impairment (MCI), who underwent positron emission tomography with Pittsburg compound B (PiB-PET). The packages were Voxel-based specific regional analysis system for Alzheimer's disease (VSRAD) and Brain anatomical analysis using DARTEL (BAAD).Subject data: Data on 65 patients diagnosed with MCI, who had undergone both sMRI scans and PiB-PET beta-amyloid imaging, were downloaded from the Alzheimer's disease neuroimaging initiative (ADNI) database. Of those 65 MCI cases, 18 were found positive by PiB-PET.Data processing: BAAD interprets sMRI both in false-color images and in Z-scores for 98 brain regions. VSRAD also gives a false-color picture, and one bilateraltwin-ROI z-score, usually for the region of the hippocampus and entorhinal cortex, with ROI-locations specified in MNI coordinates. Results: Receiver operating characteristic (ROC) curves were used to measure the reliability of each set of ROIs by the area under the curve (AUC). VSRAD gave AUC around 0.68 with its default ROIs in the medial temporal lobe. With BAAD, AUC figures depended on the ROIs chosen; AUC values ranged from 0.69 for the hippocampal regions, via 0.86 for 16 (bilateral) ROIs, to 0.98 or more with empirically selected (mostly unilateral) ROIs, not all contiguous. Conclusions:Our results indicated that the multi-ROI approach offers greater versatility and better discrimination of the amyloid-positive MCI cases, improving the prospect of data-acquisition and diagnosis earlier than the MCI stage. Both the number and selection of ROIs are crucial to accuracy. Further testing will be needed to validate ROI combinations for MCI and earlier stages, for other populations and pathologies, and for mixed pathologies.

show abstract

O4‐07‐03: Pathologic Validation of the Eadc‐adni Harmonized Hippocampal Protocol

Cited by 2 publications

References 0 publications

The CA2 hippocampal subfield in humans: A review

The CA2 hippocampal subfield in humans: A review

Diagnosis of amyloid-positive mild cognitive impairment using structural magnetic resonance imaging: The worth of multiple regions of interest

Contact Info

Product

Resources

About